Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.

"Declarations Ethics approvalAll procedures performed in this study were in accordance with the ethical standards of the International Conference on Harmonization Guidelines for Good Clinical Practice and with the 1964 Helsinki Declaration and its later amendments. The study was approved by the local institutional review board. Consent to participateAll participants provided written informed consent at enrolment. Consent to publishAll participants provided written informed consent for the publication of their data. Competing interestsThe authors declare no competing interests. AuthorshipAll listed authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data, or the creation of new software used in the work; have drafted the work or revised it critically for important intellectual content; have approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Competing interests The authors declare no competing interests."

"Funding Editorial assistance in the preparation of this article was supported by Sandoz."